EG 427

Developer of a pinpoint gene therapy designed to cure spinal cord injury-related disorders. The company develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV...

Healthcare

Paris, France

Founded 2019

23 employees

Website

Valuation

$123.9M

Market implied

Share Price

N/A

Total Raised

$48.9M

Last Round

N/A

Investors

+8 other investors

View all 8 investors

Valuation History

0 funding rounds on record

Cap Table

Ownership structure

Market Activity

Secondary transactions

Get the full picture

Create a free account to unlock EG 427's funding history, team members, investor details, and more.

15 free profiles/month · No credit card required